Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mary Weiser-evans"'
Autor:
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, Natalia J. Gurule, Andre Navarro, Anh T. Le, Amber M. Johnson, Jeff Kwak, Diana I. Polhac, Eric T. Clambey, Mary Weiser-Evans, Daniel T. Merrick, Michael C. Yang, Tejas Patil, Erin L. Schenk, Lynn E. Heasley, Raphael A. Nemenoff
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that control this response ar
Externí odkaz:
https://doaj.org/article/8192c462eff74d50be9a1f7314bb046e
Autor:
James F. Dylewski, Nancy Wilson, Sizhao Lu, Parmjit Jat, Mary Weiser-evans, Sarah E. Panzer, Judith Blaine
Publikováno v:
MethodsX, Vol 7, Iss , Pp 101048- (2020)
Glomerular endothelial cells (GEnC) are a specialized microvascular subset of endothelial cells that, when injured, result in many types of diseases within the kidney. Thus, techniques to study GEnC in a cell culture system are important to investiga
Externí odkaz:
https://doaj.org/article/e44832f63b694a0cb564d715e882979c
Autor:
John R. Montford, Allison M.B. Lehman, Colin D. Bauer, Jelena Klawitter, Jost Klawitter, Joanna M. Poczobutt, Micah Scobey, Mary Weiser-Evans, Raphael A. Nemenoff, Seth B. Furgeson
Publikováno v:
Journal of Lipid Research, Vol 59, Iss 2, Pp 380-390 (2018)
The group IVA calcium-dependent cytosolic phospholipase A2 (cPLA2α) enzyme directs a complex “eicosanoid storm” that accompanies the tissue response to injury. cPLA2α and its downstream eicosanoid mediators are also implicated in the pathogenes
Externí odkaz:
https://doaj.org/article/3b8f94ee4d0040ea8bd38c602ae9ab62
Autor:
Meredith A. Tennis, Michelle Van Scoyk, Lynn E. Heasley, Katherine Vandervest, Mary Weiser-Evans, Scott Freeman, Robert L. Keith, Pete Simpson, Raphael A. Nemenoff, Robert A. Winn
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 3, Pp 244-253 (2010)
The goal of this study was to assess the ability of iloprost, an orally active prostacyclin analog, to inhibit transformed growth of human non-small cell lung cancer (NSCLC) and to define the mechanism of iloprost's tumor suppressive effects. In a pa
Externí odkaz:
https://doaj.org/article/0d8a07f23339495ba9cabf2d87137c68
Autor:
Joanna M Poczobutt, Miguel Gijon, Jay Amin, Dwight Hanson, Howard Li, Deandra Walker, Mary Weiser-Evans, Xian Lu, Robert C Murphy, Raphael A Nemenoff
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e79633 (2013)
Eicosanoids are bioactive lipid mediators derived from arachidonic acid(1) (AA), which is released by cytosolic phospholipase A2 (cPLA2). AA is metabolized through three major pathways, cyclooxygenase (COX), lipoxygenase (LO) and cytochrome P450, to
Externí odkaz:
https://doaj.org/article/44a507f3fab74c2cb8b7f8b5518861b5
Publikováno v:
PPAR Research, Vol 2008 (2008)
Lung cancer is the leading cause of cancer death, and five-year survival remains poor, raising the urgency for new treatment strategies. Activation of PPARγ represents a potential target for both the treatment and prevention of lung cancer. Numerous
Externí odkaz:
https://doaj.org/article/3ebc5dcc60c14b3b815fbf3d40895990
Autor:
Allison Dubner, Sizhao Lu, Austin Jolly, Tysen Noble, Karen Moulton, Raphael Nemenoff, Mary Weiser-Evans
Publikováno v:
Physiology. 38
Purpose: Atherosclerosis is a major cause of morbidity and mortality worldwide, but current therapies fail to adequately meet clinical needs. Emerging evidence implicates the outer layer of the blood vessel, the adventitia, in the pathogenesis of ath
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e0d5a2d601f9000eb92d3b75fb8bd5
https://doi.org/10.1152/physiol.2023.38.s1.5733626
https://doi.org/10.1152/physiol.2023.38.s1.5733626
Autor:
Mary Weiser-Evans, Sizhao Lu
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 42:957-959
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b12177991724f9f38e182374ccbd0b9e
https://doi.org/10.1161/atvbaha.122.318009
https://doi.org/10.1161/atvbaha.122.318009
Autor:
Emily K Kleczko, Anh T Le, Trista K Hinz, Teresa T Nguyen, Andre Navarro, Cheng-Jun Hu, Eric T Clambey, Daniel T Merrick, Mary Weiser-Evans, Raphael A Nemenoff, Lynn E Heasley
Lung cancers bearing oncogenically-mutated EGFR represent a significant fraction of lung adenocarcinomas (LUADs) for which EGFR-targeting tyrosine kinase inhibitors (TKIs) provide a highly effective therapeutic approach. However, these lung cancers e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32f338a5b949527e785a45e76d967565
https://doi.org/10.1101/2022.10.26.513856
https://doi.org/10.1101/2022.10.26.513856
Autor:
Raphael Nemenoff, Emily Kleczko, Trista Hinz, Andre Navarro, Anh Le, Teresa Nguyen, Natalia Gurule, Amber Johnson, Jeff Kwak, Diana Polhac, Eric Clambey, Mary Weiser-Evans, Daniel Merrick, Michael Yang, Tejas Patil, Erin Schenk, Lynn Heasley
Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g. alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that control this response are not well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af07c9bbb2b5566a16db5514a3a4e76a
https://doi.org/10.21203/rs.3.rs-2136258/v1
https://doi.org/10.21203/rs.3.rs-2136258/v1